The short version of Visceral adipose tissue fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-15. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
== Health effects == Exposure to PFAS typically comes from consumption of PFAS contaminated food or water and inhalation of airborne PFAS. Once in the body, some PFAS have half-lives of over eight years. PFAS are not broken down in the body, but instead cleared from the body in urine. This lengthy residence time and widespread environmental contamination lead to accumulation of PFAS that may cause adverse health outcomes. Given the large diversity of PFAS compounds, there is a lack of high-quality epidemiological data on the associations between most specific PFAS chemicals and toxicological impacts.
=== Fish === A University of Florida scientist reports that male sand gobies work harder at building nests and taking care of eggs when females are present – the first time such "courtship parental care" has been documented in any species. In the cichlid species Tropheus moorii, a male and female will form a temporary monogamous pair bond and spawn; after which, the female leaves to mouthbrood the eggs on her own. T. moorii broods exhibit genetic monogamy (all eggs in a brood are fertilized by a single male). Another mouth brooding cichlid – the Lake Tanganyika cichlid (Xenotilapia rotundiventralis) has been shown that mating pairs maintain pair bonds at least until the shift of young from female to male. More recently the Australian Murray cod has been seen maintaining pair bonds over 3 years. Pair bonding may also have non-reproductive benefits, such as assisted resource defense. Recent study comparing two species of butterflyfishes, C. baronessa and C. lunulatus, indicate increase in food and energy reserves compared to individual fish.
== Spinal epidural space == In the spinal canal, the periosteal layer adheres to the inner surface of the spinal canal which is formed by the bodies of vertebrae. The meningeal layer lays over the spinal arachnoid mater. Between the vertebrae and the dural sheath is the spinal epidural space. Unlike the cranial epidural space, the spinal epidural space contains adipose tissue, the internal vertebral venous plexuses and the spinal nerve roots. The spinal epidural space spans the length of the spinal cord, from the foramen magnum superiorly to the sacral hiatus inferiorly. Epidural space is the smallest at the cervical region, measuring 1 to 2 mm. At L2 to L3, enlarges until 5 to 6 mm. It then enlarges progressively until lower lumbar and sacral region. However, some authors stated that it decreases in size after mid-lumbar region until 2 mm at S1 level.
== Further reading == Genck, Wayne (7 November 2010). "Make The Most of Antisolvent Crystallization". Chemical Processing. Putman Media. Retrieved 12 June 2025. Sheehan, David (2009). Physical Biochemistry: Principles and Applications. John Wiley & Sons. p. 285. ISBN 978-0-470-85602-4. Miller, S A; Dykes, D D; Polesky, H F (11 February 1988). "A simple salting out procedure for extracting DNA from human nucleated cells". Nucleic Acids Research. 16 (3): 1215. CiteSeerX 10.1.1.941.1917. doi:10.1093/nar/16.3.1215. PMC 334765. PMID 3344216. {{cite journal}}: Cite uses deprecated parameter |citeseerx= (help) McKay, H. A. C. (1 January 1953). "Activities and activity coefficients in ternary systems". Transactions of the Faraday Society. 49: 237–242. doi:10.1039/TF9534900237.
Sources: en.wikipedia.org
Until the early 1990s, the PLA Navy (PLAN) performed a subordinate role to the PLA Ground Force (PLAGF). Since then it has undergone rapid modernisation. The 300,000 strong PLAN is organized into three major fleets: the North Sea Fleet headquartered at Qingdao, the East Sea Fleet headquartered at Ningbo, and the South Sea Fleet headquartered in Zhanjiang. Each fleet consists of a number of surface ship, submarine, naval air force, coastal defence, and marine units. The navy includes a 25,000 strong Marine Corps (organised into seven brigades), a 18,000 strong Naval Aviation Force operating several hundred attack helicopters and fixed-wing aircraft. As part of its overall programme of naval modernisation, the PLAN is in the stage of developing a blue water navy. In November 2012, then Party General Secretary Hu Jintao reported to the CCP's 18th National Congress his desire to "enhance our capacity for exploiting marine resource and build China into a strong maritime power". According to the United States Department of Defense, the PLAN has numerically the largest navy in the world. The PLAN is led by Commander Hu Zhongming and Political Commissar is currently vacant.
Tetrameric, dimeric, and, more recently, monomeric αM protease inhibitors have been identified. α2-Macroglobulin is able to inactivate an enormous variety of proteinases (including serine-, cysteine-, aspartic- and metalloproteinases). It functions as an inhibitor of fibrinolysis by inhibiting plasmin and kallikrein. It functions as an inhibitor of coagulation by inhibiting thrombin. α2-Macroglobulin has in its structure a 35 amino acid "bait" region. Proteinases binding and cleaving the bait region become bound to α2M. The proteinase–α2M complex is recognised by macrophage receptors and cleared from the system.
=== Type I civilization methods === Large-scale application of fusion power: In terms of mass–energy equivalence, Type I implies the conversion of about 2 kg of matter to energy per second. An equivalent energy release could theoretically be achieved by fusing about 280 kg of hydrogen into helium per second, a rate roughly equivalent to 8.9×109 kg/year. One cubic kilometer of water contains about 1011 kg of hydrogen, and the Earth's oceans contain about 1.3×109 km3 of water, meaning that humans on Earth could sustain this rate of consumption over geological time scales, in terms of available hydrogen. Antimatter in large quantities would provide a mechanism to produce power on a scale several orders of magnitude beyond the current level of technology. In antimatter-matter collisions, all of the rest mass of the particles is converted to radiant energy. Their energy density (energy released per mass) is about four orders of magnitude greater than that from using nuclear fission, and about two orders of magnitude greater than the best possible yield from fusion. The reaction of 1 kg of antimatter with 1 kg of matter would produce 1.8×1017 J (180 petajoules) of energy. Although antimatter is sometimes proposed as a source of energy, this does not seem feasible. Artificially producing antimatter – according to current understanding of the laws of physics – involves first converting energy into mass, which yields no net energy.
== Structure and binding partners == Members of the CCN protein family, including CTGF, are structurally characterized by having four conserved, cysteine-rich domains. These domains are, from N- to C-termini, the insulin-like growth factor binding protein (IGFBP) domain, the von Willebrand type C repeats (vWC) domain, the thrombospondin type 1 repeat (TSR) domain, and a C-terminal domain (CT) with a cysteine knot motif. CTGF exerts its functions by binding to various cell surface receptors in a context-dependent manner, including integrin receptors, cell surface heparan sulfate proteoglycans (HSPGs), LRPs, and TrkA. In addition, CTGF also binds growth factors and extracellular matrix proteins. The N-terminal half of CTGF interacts with aggrecan, the TSR domain interacts with VEGF and, the CT domain interacts with members of the TGF-β superfamily, fibronectin, perlecan, fibulin-1, slit, and mucins.
=== Alternative medicine === The Food and Drug Administration (FDA) does not recommend alternative therapies to treat sexual dysfunction. Many products are advertised as "herbal viagra" or "natural" sexual enhancement products, but no clinical trials or scientific studies support the effectiveness of these products for the treatment of ED, and synthetic chemical compounds similar to sildenafil have been found as adulterants in many of these products. The FDA has warned consumers that any sexual enhancement product that claims to work as well as prescription products is likely to contain such a contaminant. A 2021 review indicated that ginseng had "only trivial effects on erectile function or satisfaction with intercourse compared to placebo".
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.